14 recruiting, 12 completed, 7 not yet recruiting, 4 active not recruiting. 44 Phase 1, 12 Phase 2.
Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG) HN2301 injection - Generalized Myasthenia Gravis | Phase 1 | Not yet recruiting | Shenzhen MagicRNA Biotechnology Co., Ltd | 6 | 2026-12-31 | 2026-08-12 |
| An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis EA5 - Generalized Myasthenia Gravis (gMG) | Phase 1 | Not yet recruiting | Shanghai Lanyi Therapeutics Co., Ltd. | 18 | 2026-09-15 | 2026-09-14 |
| Universal STAR-T Cell Injection in Generalized Myasthenia Gravis Universal STAR-T Cell - Generalized Myasthenia Gravis | Phase 1 | Not yet recruiting | Daishi Tian | 10 | 2026-07-06 | 2026-07-20 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| Study of Aritinercept in Patients With Generalized Myasthenia Gravis Aritinercept, Placebo - Myasthenia Gravis, Generalized | Phase 1 / Phase 2 | Recruiting | Aurinia Pharmaceuticals Inc. | 81 | 2026-04-22 | 2026-08-03 |
| Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis | Phase 1 | Recruiting | Kite, A Gilead Company | 57 | 2026-04-10 | 2026-11-17 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis IM-101 Part A, Placebo Part A, IM-101 Part B - Myasthenia Gravis | Phase 1 / Phase 2 | Recruiting | ImmunAbs Inc. | 96 | 2026-02-05 | 2026-02-11 |
| Ripertamab for the Treatment of Myasthenia Gravis ripertamab - Myasthenia Gravis (MG) | Phase 1 / Phase 2 | Not yet recruiting | Zhongming Qiu | 20 | 2026-02-01 | 2026-01-28 |
| Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) Cizutamig - Generalized Myasthenia Gravis | Phase 1 | Recruiting | Candid Therapeutics | 44 | 2025-09-16 | 2026-09-02 |
| Oxaloacetate in Myasthenia Gravis Oxaloacetate, Placebo - Myasthenia Gravis | Phase 1 | Withdrawn | University of Kansas Medical Center | 2025-08-01 | 2025-07-11 | |
| A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases LCAR-AIO T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD) | Phase 1 | Withdrawn | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-06-17 | 2026-06-24 | |
| A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders Azercabtagene zapreleucel (azer-cel) - B-cell Mediated Autoimmune Disorders | Phase 1 | Recruiting | TG Therapeutics, Inc. | 100 | 2025-05-06 | 2026-10-27 |
| UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Changzhou No.2 People's Hospital | 18 | 2025-05-01 | 2025-05-18 |
| The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis Dose level 1 group, Dose level 2 group, Dose level 3 group - Myasthenia Gravis, Generalized | Phase 1 | Active not recruiting | Ting Chang, MD | 10 | 2025-05-01 | 2026-05-27 |
| Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases anito-cel, Cyclophosphamide, Fludarabine - Muscular Diseases, Neuromuscular Manifestations | Phase 1 | Recruiting | Kite, A Gilead Company | 30 | 2025-04-30 | 2026-10-22 |
| Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis YTB323 - Generalized Myasthenia Gravis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 15 | 2025-04-22 | 2026-09-04 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis SYS6020 injection - Myasthenia Gravis | Phase 1 | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 60 | 2025-03-04 | 2026-08-12 |
| An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis GC012F injection - Generalized Myasthenia Gravis (gMG) | Phase 1 | Not yet recruiting | Chongbo Zhao | 18 | 2025-02-15 | 2025-01-06 |
Showing 20 of 44. Sign in to see all of them.
Myasthenia Gravis (34) · Multiple Sclerosis (9) · Neuromyelitis Optica (9) · Lupus Erythematosus, Systemic (4) · Myelitis, Transverse (4) · Myositis (4) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (4) · Scleroderma, Systemic (4) · Autoimmune Diseases (3) · Zollinger-Ellison Syndrome (3) · ACTH Syndrome, Ectopic (2) · Adrenal Cortex Neoplasms (2) · Autoimmune Diseases of the Nervous System (2) · Carcinoma, Medullary (2) · Carcinoma, Merkel Cell (2)
Neoplasms (44) · Neoplasms by Site (42) · Nervous System Diseases (40) · Nervous System Neoplasms (39) · Neurodegenerative Diseases (39) · Paraneoplastic Syndromes, Nervous System (39) · Immune System Diseases (37) · Autoimmune Diseases of the Nervous System (36) · Autoimmune Diseases (35) · Neuromuscular Junction Diseases (34) · Neuromuscular Diseases (33) · Demyelinating Autoimmune Diseases, CNS (13) · Demyelinating Diseases (13) · Cranial Nerve Diseases (10)
Cyclophosphamide (5) · fludarabine (4) · Rituximab (3) · Acetates (1) · Capecitabine (1) · Clopidogrel (1) · Dexlansoprazole (1) · Esomeprazole (1) · Everolimus (1) · Exercise (1) · Granulocyte Colony-Stimulating Factor (1) · Hematopoietic Stem Cell Transplantation (1) · Hizentra (1) · LFB-R603 (1) · Lansoprazole (1)
Cabaletta Bio (2) · Kite, A Gilead Company (2) · Ting Chang, MD (2) · Abide Therapeutics (1) · Aurinia Pharmaceuticals Inc. (1) · Baltimore VA Medical Center (1) · COUR Pharmaceutical Development Company, Inc. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Candid Therapeutics (1) · Changzhou No.2 People's Hospital (1) · Chongbo Zhao (1) · Corcept Therapeutics (1) · Crinetics Pharmaceuticals Inc. (1) · CuraVac (1) · Daishi Tian (1)
United States (23) · China (16) · United Kingdom (3) · Belgium (2) · France (2) · Spain (2) · Australia (1) · Bulgaria (1) · Canada (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Poland (1) · Serbia (1)
Daishi Tian (2) · Andreas G Moraitis, MD (1) · Anu Jacob, MD DM FRCP (1) · Benjamin Greenberg, MD (1) · Bruce Cree, MD, PhD (1) · Charlene E Hafer-Macko, MD (1) · Chuan Qin (1) · Ghazala Hayat, M.D. (1) · He Huang, MD (1) · Jacqueline Palace, FRCP DM (1) · Jafar Kafaie, M.D. (1) · James Yao (1)
PMID 19838774, PMID 20606544, PMID 21211990, PMID 22464259, PMID 23333143, PMID 25900182, PMID 39720510, PMID 41747738
2015 (1), 2023 (1), 2025 (1), P30CA016672 (1), U01CA062461 (1)